Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 9
Submit an article Journal homepage
951
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience

Filiz YucebayDepartment of Pharmacy, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6861-3546
ORCID Icon,
Christina MatthewsDepartment of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA;
,
Marcin PutoDepartment of Pharmacy, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, USA;
,
Junan LiCollege of Pharmacy, Ohio State University, Columbus, Ohio, USA;
,
Basem WilliamDivision of Hematology, Department of Internal Medicine, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Samantha M. JaglowskiDivision of Hematology, Department of Internal Medicine, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Sam L. PenzaDivision of Hematology, Department of Internal Medicine, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Sumithira VasuDivision of Hematology, Department of Internal Medicine, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Don M. BensonDivision of Hematology, Department of Internal Medicine, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Leslie A. AndritsosDivision of Hematology, Department of Internal Medicine, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Steven M. DevineDivision of Hematology, Department of Internal Medicine, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
,
Yvonne A. EfeberaDivision of Hematology, Department of Internal Medicine, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
&
Julianna V. F. RoddyDepartment of Pharmacy, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, USA;
show all
Pages 2223-2229 | Received 25 Oct 2018, Accepted 16 Jan 2019, Published online: 15 Feb 2019

References

  • Garnett C, Apperley JF, Pavlů J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013;4:366–378.
  • Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. The Lancet Haematology. 2015;2:e21–e29.
  • Berger M, Biasin E, Saglio F, et al. Innovative approaches to treat steroid-resistant or steroid refractory GVHD. Bone Marrow Transplant. 2008;42:S101–S105.
  • Deeg HJ. How I treat refractory acute GVHD. Blood 2007;109:4119–4126.
  • Markey KA, MacDonald KP, Hill GR. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 2014;124:354–362.
  • Actemra (tocilizumab) [prescribing information]. San Francisco, CA: Genetech Inc; 2014.
  • Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17:1862–1868.
  • Roddy JV, Haverkos BM, McBride A, et al. Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2016;57:81–85.
  • Przepiorka D, Martin P, Klingemann HG, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828.
  • Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009;114:891–900.
  • Ganetsky A, Hexner EO, Loren A, et al. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplant 2018; [cited 2018 May 24].
  • Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. The Lancet Oncology. 2014;15:1451–1459.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.